Hims & Hers Health (HIMS) is up about 6% as traders react to renewed optimism that U.S. regulators may ease limits on certain wellness peptides. The stock has been benefiting from momentum around a potential regulatory opening that could allow broader commercialization of peptide-based treatments, a category investors view as adjacent to (and potentially complementary with) weight-loss and metabolic health demand.

A friendlier framework for peptides would expand the menu of therapies Hims can offer through its direct-to-consumer telehealth platform. Investors are treating the FDA’s planned review process as a possible pathway to a clearer rulebook—reducing uncertainty that has weighed on parts of the broader compounded-therapy ecosystem—while creating a new growth narrative beyond the company’s current headline categories.

The peptide-driven rally has landed on top of a market already sensitive to changing sentiment on Hims’ regulatory and partnership outlook. In recent sessions, the shares also saw incremental support from bullish analyst actions, including a raised price target from Bank of America, which helped keep attention on the name as investors reassess risk and potential upside scenarios.

Near-term trading will likely track follow-through on the FDA’s peptide review timeline and any added clarity on which substances could move into a more permissive pathway. Investors will also watch for operational signals—such as product readiness, supply/manufacturing capabilities, and marketing rollout plans—that could indicate whether Hims can translate regulatory momentum into measurable revenue and margin impact.